



(51) International Patent Classification:

A61K 39/00 (2006.01) A61K 9/16 (2006.01)
A61K 35/00 (2006.01) C12N 7/00 (2006.01)

(21) International Application Number:

PCT/US2021/041192

(22) International Filing Date:

10 July 2021 (10.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/050,629 10 July 2020 (10.07.2020) US

(71) Applicant: **ICONIC THERAPEUTICS, INC.** [US/US];
701 Gateway Blvd, Ste 100, South San Francisco, California
94080 (US).


(72) Inventors: **MIGONE, Thi-Sau**; c/o ICONIC THERA-
PEUTICS, INC., 701 Gateway Blvd, Ste 100, South San
Francisco, California 94080 (US). **GREENE, William**; c/o
ICONIC THERAPEUTICS, INC., 701 Gateway Blvd, Ste
100, South San Francisco, California 94080 (US).

(74) Agent: **MUBYANA, Kuwabo** et al.; Goodwin Procter
LLP, 100 Northern Avenue, IP DOCKETING DEPT./7TH
FL, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: INFLAMMATORY DISEASE TREATMENT USING ANTI-TISSUE FACTOR ANTIBODIES



* $p < 0.05$ ** $p < 0.01$ *** $p < 0.005$ **** $p < 0.0001$, versus Vehicle, ANOVA

FIG. 15

(57) Abstract: Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs for treatment of inflammatory diseases. Also provided herein are methods of treating subjects having inflammatory diseases by administering the anti-TF antibodies or ADCs.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*